Enhancement of the Th1 cytokine response of bacillus Calmette-Guerin and streptococcal preparation OK-432 (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Enhancement of the Th1 cytokine response of bacillus Calmette-Guerin and streptococcal preparation OK-432 (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 37:A3308 1996. Unique Identifier : AIDSLINE ICDB/97633308
Fujimoto T; O'Donnell MA; Mai M; Duda RB; Beth Israel Hosp., Harvard Medical Sch., Boston, MA, 02215

Abstract: In cancer immunotherapy with biological response modifiers (BRM) such as bacillus Calmette-Guerin (BCG) or streptococcal preparation OK-432, induced interferon-gamma (IFN-gamma) plays a crucial role in the inhibition of tumor growth. This study was undertaken to determine whether additional cytokines would further enhance IFN-gamma production when added to these BRMs. IFN-gamma production by mouse splenocytes followed a parabolic dose-response curve to each BRM. When stimulated with BCG, IFN-gamma production was substantially enhanced by the addition of IL-2, IL-12, IL-15, or GM-CSF. OK-432 was a stronger IL-12 and IFN-gamma inducer than BCG. Furthermore, IFN-gamma production with OK-432 was enhanced by the addition of IL-2, IL-12, or IL-15, but not by GM-CSF. IL-10 or antibody to IL-12 markedly inhibited IFN-gamma production by both BRMs. These results suggest that both BCG and OK-432 are potent immunostimulators of the Th1 cytokine response and that this response can be accelerated by the rational addition of other cytokines.
Keywords: *Adjuvants, Immunologic Animal *BCG Vaccine Cytokines/*BIOSYNTHESIS Mice Th1 Cells/*METABOLISM ABSTRACTKWDadjuvants,immunologicanimalKWDbcgvaccinecytokines/KWDbiosynthesismiceth1cells/KWDmetabolismabstract
970330
M9731542

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .